Why it matters: UnitedHealth Group’s $90,000 third-quarter hiring of Penn Avenue Partners represents a strategic defense move. The healthcare giant faces intense bipartisan congressional pressure over pharmacy benefit manager practices and Medicare Advantage costs. This adds firepower to an already formidable in-house operation that has spent over $82 million since 2003.

By the numbers

UnitedHealth maintains extensive lobbying operations across multiple firms. Internal spending has exceeded $82 million over two decades. External partnerships include long-term relationships with Avenue Solutions (76 disclosures) and Fierce Government Relations (64 disclosures). The Penn Avenue team includes three lobbyists: Jay J. Sulzmann, Sidney Jerome Rosenbaum III, and Timothy Farrell Hannegan.

Broader context

Congress is pursuing aggressive healthcare cost reforms with bipartisan momentum. Lawmakers from both parties are targeting pharmacy benefit managers and Medicare Advantage overpayments. Recent hearings have featured sharp criticism of industry practices that directly impact UnitedHealth’s business model.

The agenda

The Q3 2025 filing targets health issues, pharmacy benefit matters, and Medicare/Medicaid policy. Key congressional focus areas include PBM transparency legislation and Medicare Advantage oversight reforms. UnitedHealth operates Optum Rx, one of the nation’s largest pharmacy benefit managers.

Competitive landscape

The entire healthcare industry is heavily engaged on these issues. UnitedHealth’s own 2025 Q2 report shows multi-million dollar quarterly investments. Pharmaceutical companies, hospital associations, and insurance groups are all lobbying extensively on PBM and Medicare Advantage reforms.

Between the lines

Recent congressional activity directly threatens UnitedHealth’s operations. The Senate Judiciary Committee hearing on PBM competition featured harsh criticism from Sen. Chuck Grassley. A Ways and Means Committee hearing highlighted $84 billion in annual Medicare Advantage overpayments. Rep. Lloyd Doggett and Rep. Greg Murphy launched a bipartisan investigation into vertical consolidation, specifically targeting UnitedHealth. Legislation includes the Pharmacy Benefit Manager Transparency Act and Patients Before Middlemen Act.

The bottom line

UnitedHealth’s hiring of Penn Avenue reflects defensive positioning against sustained congressional pressure. The firm’s elite congressional experience, particularly Sulzmann’s Senate HELP Committee background, provides crucial expertise for navigating hostile legislative terrain.

All data used in this article came from Legis1. Request a demo to learn more!

Spot something wrong? Report an issue with this article